Cingulate Inc. (CING) Stock Profile — Insider Trades & Financials

Net Income-$6.3M

EPS$-3.60

Market Cap$68.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Shane Schaffer

CEO & Executive Director

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The companyâs lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Founded: 2012
Employees: 14
Headquarters: Kansas City, Kansas, United States

⚡

Core Efficiency

ROE?

-250.03%

ROA?

-41.62%

D/E Ratio?

5.01

📊

Profitability Ratios

Current Ratio?

1.16

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 3, 2026 (in 147 days)

Annual Report (10-K) — Based on filing pattern

Sep 3, 2026

Predicted10-K

Mar 18, 2026

10-KQ4 20255d after period end

Mar 18, 2026

10-KFY 202577d after period end

Nov 13, 2025

10-QQ3 20252d after period end

Aug 19, 2025

10-QQ2 20254d after period end

May 8, 2025

10-QQ1 20251d after period end

Mar 27, 2025

10-KQ4 20246d after period end

Mar 27, 2025

10-KFY 202586d after period end

Nov 7, 2024

10-QQ3 20241d after period end

Loading company sections...

Cingulate Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness